AUSTIN, June 2013: OriGen Biomedical, Inc. announced the acquisition of Alliance Pharmaceutical Corp.’s, San Diego, CA, LiquiVent® clinical trial data to be used in future US Food & Drug Administration submissions. This perfluorochemical product went through clinical trials in the 1990’s and early 2000’s involving treatment of acute respiratory distress syndrome with Partial Liquid Ventilation (PLV) but ultimately did not receive final clearance by the FDA. Patients in the studies did show enhanced pulmonary mechanics and oxygenation compared to standard therapy.

In 2001, Dr. Wedel, MD, JD, FACP, the LiquiVent program director noted that, “during the course of evaluating LiquiVent in pre-clinical and clinical studies, a great deal of knowledge has been gained regarding the use of perflubron for the treatment of various types of lung injury and as a safe vehicle for drug delivery.”¹

OriGen also applied and was awarded the trademark to assure our customers that it was the same quality as the PFB used in the Alliance Clinical Trials. OriGen Biomedical will be replacing its current PFB product, Perflurobronc, and rebranding it as Liquivent®. OriGen is excited to explore uses for bronchoalveolar lavage (BAL) with this pharmaceutical grade perfluorocarbon compound, Perflubron (perfluoroctyl bromide or PFB).

CONTACT:
OriGen Biomedical, Inc.
marketing@origenbio.com
512-474-7278